Plasma Thrombin-Antithrombin Complexes, Latent Coagulation Disorders and Metastatic Spread in Lung Cancer: A Longitudinal Study

Oncology (Switzerland)

Volumn 53, Issue 6, 1996, Pages 455-460

  Tricerri, Augusto ^a   Vangeli, Marcello ^a   Errani, Andrea R ^a   Guidi, Luisa ^a   Canetta, Mattia ^a   Vaccarino, Marco ^b   De Santis, Carlo ^c   Ipsevich, Francesco ^c   Salvati, Francesco ^b   Bartoloni, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b VIII Divisione Pneumologia   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Antithrombin III; Coagulation; Lung cancer; Metastasis; Thrombin antithrombin III complexes

Indexed keywords

ANTITHROMBIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; THROMBIN; VINBLASTINE; VINCRISTINE;

ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CANCER GROWTH; CANCER RECURRENCE; CONTROLLED STUDY; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOEMBOLISM;

ANTITHROMBIN III; BLOOD COAGULATION DISORDERS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; HUMANS; LONGITUDINAL STUDIES; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PEPTIDE HYDROLASES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 10544231049     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227620     Document Type: Article

References (25)

1. Nand S: Haemostasis and cancer, Cancer J 1993;6:54-58.
2. Nand S, Mcssmorc H: Haemostasis in malignancy, Am J Hcmatol 1990;35:45-55.
3. Van Wersch JWJ, Tjwa MKT: Coagulation/ fibrinolysis balance and lung cancer, Haemostasis 1991:21:117-123.
4. Bartoloni C, Guidi L, Marciano M, Patriarca F, Gentiloni N, Pili R, Cursi F, Gambassi G: Thrombin-antithrombin complexes in human cancer, Abstract Book of the 10th Meeting of the European Association for Cancer Research, Galway, Sept 1989, p 16.
5. Bartoloni C, Guidi L, Tricerri A, Patriarca F, Cursi F, Canctta M, Cappelli A, Vangeli M, Salvati F, Gambassi G: Latent coagulation disorders evaluated by the assay of plasma thrombin-antithrombin III complexes in a large scries of ‘solid tumours’, Oncology 1992:49:426-430.
6. Rocha E, Paramo JA, Fernandez FJ, Cuesta B, Hernandez M, Paloma MJ, Rifon J: Clotting activation and impairment of fibrinolysis in malignancy, Thromb Res 1989;54:699-707.
7. Lindahl AK, Sandset PM, Abildgaard U: Indices of hypercoagulation in cancer as compared with those in acute inflammatory and acute infarction, Haemostasis 1990;20:253-262.
8. Van Wersch JWJ, Peters C, Ubachs HMH: Haemostasis activation markers in plasma of patients with benign and malignant gynaecological tumours: A pilot study, EurJ Clin Chcm Clin Biochem 1995;33:225-229.
9. Kemkes-Matthes B, Bleyl H: Factor IX,-anti-thrombin (IX, AT) and thrombin-antithrombin (TAT) complexes in lung cancer patients, Ann Hematol 1992;64:35-39.
10. Zacharski LR, Donati MB, Rickies FR: Registry of clinical trials of antithrombotic drugs in cancer: Second report, Thromb Haemost 1993; 70:357-360.
11. Zacharski LR: Mechanism of inhibition of cancer dissemination by warfarin; in Honn KV, Powers WE, Sloanc BF (cds): Mechanism of Cancer Metastases: Potential Therapeutic Implications, Boston, Nijhoff, 1986, pp 145-148.
12. Zacharski LR, Henderson PD, Rickies FR, Forman WB, Cornell CJ, Forcier RJ, Edwards RL, Headley E, Kim SH, O’Donnell JF: Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck and prostate: Final report of VA cooperative study n, 75, Cancer 1984;53:2046-2052.
13. Lebeau B, Chastang CL, Brechol JM: The treatment with subcutaneous heparin increases the complete response and overall survival in SCLC, Lung Cancer 1991;7(suppl): 129- 132.
14. Neumann S, Gunzcr G, Hcnnrich N, Lang H: PMN-elastase assay: Enzyme immunoassay for human PMN elastase complexcd with proteinase inhibitors, J Clin Chem Clin Biochem 1984;22:693-697.
15. Brower MS, Harpel PC: Alpha-antitrypsin-human leukocyte elastase complexes in blood: Quantification by an enzyme-linked differential antibody immunosorbent assay and comparison with alpha-2-plasmin complexes, Blood 1983;61:842-849.
16. Gordon SG, Benson B: Analysis of serum cancer procoagulant activity and its possible use as a tumour marker, Thromb Res 1989;56:431-440.
17. Francis JL, El-Baruni K, Gordon SG: Factor X activity and cancer procoagulant in malignant tissue, Abstract book of the 2nd International Congress on Advances in Management of Malignancies, Ascoli Piceno, May-June 1990, p 62.
18. Camacho M, Fabra Fras A, Llorcns A, Rutllant ML: Urokinase plasminogen activator in human tumours, Abstract book of the Metastasis Congress, 2nd International Conference of Metastasis Research Society, Heidelberg, Sept 1988, p 34.
19. Dano K, Andreasen PA, Grondahl-Hansen J, Kristenscn P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation and cancer, Adv Cancer Res 1985:44:139-266.
20. Kies MS, Posch JJ; Giolma JP, Rubin RN: Haemostatic function in cancer patients, Cancer 1980;46:831-837.
21. Soong BCF, Miller SP: Coagulation disorders in cancer, III, Fibrinolysis and inhibitors, Cancer 1970;25:867-874.
22. Patterson WP, Ringenberg QS: The pathophysiology of thrombosis in cancer, Semin Oncol 1990;17:140-146.
23. Seitz R, Rappe N, Kraus M, Wolf M, Maasbcrg M, Egbing R, Pfab R, Havemann K: Activation of coagulation and fibrinolysis in patients with lungcancer: Relation to tumour stage and prognosis, Blood Coagul Fibrinolysis 1993;4:249-254.
24. Wagner C, Dati F, Pelzer H: Quantitation of hypercoagulability associated with malignancies by thrombin-antithrombin III complexes, Abstract book of the 2nd International Congress on Advances in Management of Malignancies, Ascoli Piceno, May-June 1990, p 149.
25. Zurbon KH, Gram J, Glander K, Delbruck K, Pelzer H, Loffer H, Bruhn HD: Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin’s lymphomas and acute leukemias, Eur J Haematol 1991;47:55-59.